

Jurilab Appoints New CEO

Kuopio/Helsinki, Finland 24th April, 2008 – Jurilab today announced the appointment of Carl T. Foster, MBA, MS (biochemistry) as the company's new Chief Executive Officer. The new lead of the Finnish genetic discovery company brings a wealth of experience in the healthcare and finance industries.

Prior to joining Jurilab, Carl T. Foster was Vice President, Alliance Management for Nanogen, a San Diego-based diagnostic company and collaboration partner to Jurilab. Previously Mr. Foster has also held Vice President-level positions with companies such as King Pharmaceuticals, Oxford GlycoSciences and Praecis Pharmaceuticals and he was the General Manager of Intracel BV, a Netherlands-based immunology company. Prior to that he was with Merck, Inc. and Astra Merck where he held increasing levels of responsibility in sales, marketing, product development, and business development.

Mr. Foster has served as an advisor to pharmaceutical and biotechnology companies as a consultant and as a Managing Director with Ferghana Partners, Inc., an international investment banking group in New York.

Oy Jurilab Ltd.

Jurilab is a leader in the discovery of proprietary genes and genetic markers associated with the root cause of common diseases. These markers enable developments in diagnostic, therapeutic and preventative healthcare. Initial focus has been on the complex of diseases that form the Metabolic Syndrome or Syndrome X, including: Type 2 Diabetes, Obesity, Dyslipidemias, Hypertension and Coronary Heart Disease.

The products resulting from the genetic discovery R&D programs are therapeutic targets, diagnostic markers and test contents:

- Therapeutics – Drug Target Candidates, Companion Diagnostics
- Clinical Diagnostics (Predisposition Tests, Pharmacogenomics)
- Nutritional Targets and Diagnostics

www.jurilab.com



Oy Jurilab Ltd.

Microkatu 1
FI-70210 Kuopio, FINLAND

Phone +358 (0)20 7219 200
Fax +358 (0)20 7219 201

info@jurilab.com
www.jurilab.com

VAT FI06011325